Regeneron Pharmaceuticals Inc (NASDAQ:REGN) CFO Sells $245,028.00 in Stock

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) CFO Robert E. Landry sold 400 shares of the company’s stock in a transaction dated Monday, June 29th. The stock was sold at an average price of $612.57, for a total value of $245,028.00. Following the completion of the transaction, the chief financial officer now owns 24,334 shares of the company’s stock, valued at $14,906,278.38. The transaction was disclosed in a filing with the SEC, which is available at this link.

Shares of NASDAQ:REGN opened at $622.45 on Friday. Regeneron Pharmaceuticals Inc has a 52-week low of $271.37 and a 52-week high of $646.33. The firm has a market capitalization of $68.61 billion, a P/E ratio of 31.28, a P/E/G ratio of 1.97 and a beta of 0.58. The stock has a 50 day moving average price of $595.43 and a 200-day moving average price of $478.59. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.49 and a current ratio of 4.21.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $6.60 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.13 by $0.47. Regeneron Pharmaceuticals had a return on equity of 24.94% and a net margin of 28.56%. The firm had revenue of $1.83 billion during the quarter, compared to analyst estimates of $1.81 billion. During the same quarter in the prior year, the company earned $4.45 EPS. The business’s revenue was up 6.8% compared to the same quarter last year. On average, equities analysts forecast that Regeneron Pharmaceuticals Inc will post 23.48 EPS for the current fiscal year.

Large investors have recently made changes to their positions in the company. OmniStar Financial Group Inc. bought a new position in shares of Regeneron Pharmaceuticals in the 1st quarter worth approximately $28,000. CX Institutional increased its position in Regeneron Pharmaceuticals by 144.0% during the 1st quarter. CX Institutional now owns 61 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 36 shares in the last quarter. Parkside Financial Bank & Trust increased its position in Regeneron Pharmaceuticals by 44.2% during the 1st quarter. Parkside Financial Bank & Trust now owns 62 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 19 shares in the last quarter. Globeflex Capital L P bought a new position in Regeneron Pharmaceuticals during the 1st quarter valued at approximately $31,000. Finally, Americana Partners LLC bought a new position in Regeneron Pharmaceuticals during the 4th quarter valued at approximately $39,000. 68.04% of the stock is owned by hedge funds and other institutional investors.

REGN has been the subject of a number of research reports. JPMorgan Chase & Co. upped their price objective on Regeneron Pharmaceuticals from $375.00 to $429.00 and gave the stock a “neutral” rating in a report on Wednesday, April 15th. Credit Suisse Group upped their price objective on Regeneron Pharmaceuticals from $605.00 to $700.00 and gave the stock an “outperform” rating in a report on Wednesday, June 24th. Jefferies Financial Group increased their target price on Regeneron Pharmaceuticals from $657.00 to $691.00 and gave the company a “buy” rating in a report on Friday, June 12th. Canaccord Genuity increased their target price on Regeneron Pharmaceuticals from $575.00 to $630.00 and gave the company a “buy” rating in a report on Wednesday, May 6th. Finally, BidaskClub cut Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, June 10th. Fifteen investment analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the company. The company has an average rating of “Buy” and an average price target of $550.64.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Recommended Story: Arbitrage

Insider Buying and Selling by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.